Short Interest in Virios Therapeutics, Inc. (NASDAQ:VIRI) Decreases By 59.5%

Virios Therapeutics, Inc. (NASDAQ:VIRIGet Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 91,000 shares, a decrease of 59.5% from the January 15th total of 224,900 shares. Based on an average daily volume of 264,600 shares, the days-to-cover ratio is presently 0.3 days.

Virios Therapeutics Stock Performance

NASDAQ VIRI remained flat at $0.42 on Monday. 193,858 shares of the company’s stock were exchanged, compared to its average volume of 361,360. Virios Therapeutics has a 52 week low of $0.28 and a 52 week high of $2.42. The company has a market capitalization of $8.06 million, a PE ratio of -1.27 and a beta of 1.92. The business has a fifty day moving average price of $0.57 and a 200 day moving average price of $0.81.

Virios Therapeutics (NASDAQ:VIRIGet Free Report) last issued its earnings results on Monday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. As a group, sell-side analysts anticipate that Virios Therapeutics will post -0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Virios Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Belvedere Trading LLC bought a new position in Virios Therapeutics in the second quarter worth $25,000. Envestnet Asset Management Inc. lifted its holdings in shares of Virios Therapeutics by 576.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 109,196 shares of the company’s stock valued at $26,000 after acquiring an additional 93,050 shares during the period. State Street Corp bought a new position in shares of Virios Therapeutics during the second quarter valued at $45,000. Citadel Advisors LLC bought a new position in shares of Virios Therapeutics during the second quarter valued at $46,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Virios Therapeutics by 33.3% in the fourth quarter. Renaissance Technologies LLC now owns 235,400 shares of the company’s stock valued at $56,000 after buying an additional 58,800 shares during the last quarter. Institutional investors and hedge funds own 10.96% of the company’s stock.

About Virios Therapeutics

(Get Free Report)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Read More

Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.